Mereo Biopharma Group Plc ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.54 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $0.28Price as of 23 Oct 2026 Data confidence Sign in to view data confidence Market Cap $45M Enterprise Value $14.9M Shares Outstanding 159.7M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Mereo is a clinical-stage rare-disease developer whose business economics depend on partnerships, licensing milestones and future royalties rather than recurring product sales. The portfolio offers several paths to progress, but the failed primary endpoints in the setrusumab Phase 3 studies have made regulatory engagement the central near-term issue. Alvelestat is Phase 3 ready but still needs a funded partner, while vantictumab development is led by āshibio. At 30 Jun 2026, the company held $30.1 million in cash and carried no debt, but trailing 12-month results included a $41.9 million net loss and negative free cash flow of $25.3 million. A neutral view is warranted while Mereo tests whether setrusumab has a credible pediatric path and preserves liquidity. The view would become constructive with regulatory clarity and funded alvelestat development, or cautious if both paths stall as cash declines. Sources: 0001193125-26-343533#income_statement_metrics; 0001193125-26-343533#cash_flow_metrics; 0001193125-26-343533#balance_sheet_metrics; 0001193125-26-343533#business_analysis.risk_assessment; 0001193125-26-343533#business_analysis.innovation_and_rd This section is the 12-month view: analyst targets and the scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$1.00 Mean target$2.00 High · most bullish analyst$3.01 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case supports a cautious view. Setrusumab failed to meet the primary endpoints in both Phase 3 studies, creating substantial uncertainty over approval, milestones, royalties and the value of Mereo’s retained EU and UK rights. Alvelestat requires a partner before its Phase 3 program can advance, while vantictumab execution rests with āshibio. The company also remains loss-making, with a trailing 12-month net loss of $41.9 million and negative free cash flow of $25.3 million through 30 Jun 2026. Continued delays could shorten the projected runway into mid-2027 and increase reliance on external capital. The view would move to neutral if regulators accept a defined setrusumab path, alvelestat receives committed funding and cash consumption moderates. Sources: 0001193125-26-343533#income_statement_metrics; 0001193125-26-343533#cash_flow_metrics; 0001193125-26-343533#business_analysis.risk_assessment; 0001193125-26-343533#business_analysis.regulatory_and_legal Base CaseCentral scenario The base case supports a neutral view. Mereo has multiple rare-disease assets, established collaborators and no debt, but remains dependent on clinical, regulatory and partnering outcomes rather than recurring product revenue. The failed primary endpoints in the setrusumab Phase 3 studies materially reduced certainty around the lead program, while alvelestat still requires a funded partner. Cash of $30.1 million at 30 Jun 2026 provides near-term operating capacity, although trailing 12-month free cash flow was negative $25.3 million. The view would become constructive if setrusumab gains a credible pediatric regulatory path and alvelestat secures funded Phase 3 development, or cautious if those paths stall and liquidity declines without new partnership funding. Sources: 0001193125-26-343533#balance_sheet_metrics; 0001193125-26-343533#cash_flow_metrics; 0001193125-26-343533#business_analysis.risk_assessment; 0001193125-26-343533#business_analysis.innovation_and_rd Bull CaseUpside scenario The bull case relies on a successful regulatory path forward for setrusumab in pediatric osteogenesis imperfecta (OI) patients despite missing primary fracture-rate endpoints, alongside securing a high-value strategic partnership to fund and execute the Phase 3 trial of alvelestat in AATD-LD. Scenarios are anchored to street consensus at the research date, with our rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |